Naltrexone beyond Psychiatric Domain by Ashutosh Garg, Khyati Thapliyal, Vivek Pal Singh

“…Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. …”
Get full text

Low-dose naltrexone as a treatment for vulvodynia: A case series by Renee T. Sullender, R. Gina Silverstein, Diamond M. Goodwin, Asha B. McClurg, Erin T. Carey

Subjects: Get full text

Highly multiplexed design of an allosteric transcription factor to sense new ligands by Kyle K. Nishikawa, Jackie Chen, Justin F. Acheson, Svetlana V. Harbaugh, Phil Huss, Max Frenkel, Nathan Novy, Hailey R. Sieren, Ella C. Lodewyk, Daniel H. Lee, Jorge L. Chávez, Brian G. Fox, Srivatsan Raman

“…The structure of a naltrexone-bound design shows shape-complementary methionine-aromatic interactions driving ligand specificity. …”
Get full text

Graphene-cobalt hexacyanoferrate modified sensor doped with molecularly imprinted polymer for selective potentiometric determination of bupropion by Eman M. Moaaz, Ahmed S. Fayed, Mamdouh R. Rezk, Ezzat M. Abdel-Moety

“…Molecularly imprinted polymer (MIP) approach was employed to resolve the selectivity problem of analyzing bupropion in presence of naltrexone for obesity management. Scanning electron microscope and Fourier-transform infrared were utilized to characterize the fabricated composite and the MIP. …”
Get full text

Odevixibat treatment in a child with hypoplastic left heart syndrome and severe cholestatic pruritus: a case report by Rainer Ganschow, Christof Maucksch, Peter Rauschkolb, Martin B. E. Schneider

“…Portal hypertension was evident on imaging, and the patient was experiencing severe itching attacks that did not respond to treatment with naltrexone, ursodeoxycholic acid, dimetindene, or rifampicin. …”
Get full text

Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release... by Gavin Bart, Kelly S. Barth, Paulette Baukol, Eva Enns, Udi E. Ghitza, Jacklyn Harris, Eve Jelstrom, Jane M. Liebschutz, Kara M. Magane, Delia Voronca, Zoe M. Weinstein, P. Todd Korthuis

“…., methadone, buprenorphine, and extended-release naltrexone) recruit and randomize hospitalized patients with OUD who have not been on MOUD in the fourteen days prior to hospitalization. …”
Get full text